Scientific and Production Company “Microkhim” and the Institute of Cardiology named after academician ND Strazhesko of the National Academy of Medical Sciences of Ukraine signed a memorandum of cooperation in order to ensure uninterrupted access of Ukrainian patients suffering from pulmonary arterial hypertension (PAH) to a modern domestic drug.
Cooperation involves not only the full and free provision of all patients diagnosed at the Institute with a domestic drug “NO-LAG”, but also the implementation of more in-depth individual approaches to treatment with this drug based on therapeutic drug monitoring (TLM).
“The market for drugs for the treatment of orphan diseases is very specific,” said Irina Skorohod, First Deputy General Director of Microkhim. Such diseases are not widespread, therefore, as a rule, only transnational pharmaceutical giants can afford the development and release of drugs for their treatment. The price of these drugs, respectively, is very high. It is in orphan drugs that such categories as social significance and the economics of their production are in conflict, as a result of which this group of patients becomes more vulnerable. Especially in Ukraine.
Knowing all this, we took up the challenge – and a year ago we created the generic drug “NO-LAG” for the treatment of pulmonary arterial hypertension. It is several times cheaper than the original drug, and imported generic copies. To our compatriots who need it, we will now transfer the drug for free with the assistance of the Institute of Cardiology. This is a real help to specific people in the treatment of a serious illness. In this we see the company’s social mission: to help those who need it most whenever possible. ”
It should be noted that the drug “NO-LAG” was developed on the recommendation of the head of the department of symptomatic hypertension of the Institute of Cardiology, Professor Yu.N. Sirenko. The staff of the enterprise sees continued cooperation not only in the free provision of patients with this drug. Together with the department headed by Professor Yu.N. Sirenko, Microkhim plans to launch the introduction of more targeted treatment using therapeutic drug monitoring. Such approaches are the basis of individual medicine and are already widely used in world practice.
NO-LAG is a generic of the original drug REVATIO (Pfizer), whose bioequivalence was proved in an open randomized study with the participation of 48 healthy volunteers in 2017.
At present, in Ukraine there are (officially!) Fewer than 1000 patients with pulmonary arterial hypertension, among whom about two thirds are women.
Without specific treatment, the disease is characterized by an extremely unfavorable outcome. Survival of patients over 3 years is less than 50%, while on the background of continuous therapy, such patients can live for decades.